Associated Papers
Genetic polymorphisms associated with upper gastrointestinal bleeding: a systematic review.
Forgerini M et al.
The Pharmacogenomics Journal, 2021
Assessment of pharmacogenomic SLCO1B1 assay for prediction of neuromuscular pain in type 2 diabetes mellitus and cardiovascular patients: preliminary results.
Licito A et al.
European Review for Medical and Pharmacological Sciences, 2020
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.
Zhou Y et al.
Clinical Pharmacology and Therapeutics, 2017
Effects of functional CYP2C8,CYP2C9,CYP3A5,and ABCB1 genetic variants on the pharmacokinetics of insulin sensitizer pioglitazone in Chinese Han individuals.
Yin SJ et al.
Pharmacogenetics and Genomics, 2017
Pharmacogenetics in Jewish populations.
Yang Y et al.
Drug Metabolism and Drug Interactions, 2014
Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes.
Martis S et al.
The Pharmacogenomics Journal, 2013
Prevalence of CYP2C8 polymorphisms in a North Indian population.
Minhas S et al.
Genetics and Molecular Research : Gmr, 2013
Frequencies of Cytochrome P450 2B6 and 2C8 Allelic Variants in the Mozambican Population.
Arnaldo P et al.
The Malaysian Journal of Medical Sciences : Mjms, 2013
The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPARγ on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes.
Stage TB et al.
Pharmacogenetics and Genomics, 2013
CYP2C19*17 gain-of-function polymorphism is associated with peptic ulcer disease.
Musumba CO et al.
Clinical Pharmacology and Therapeutics, 2013
Genetic polymorphisms of CYP2C8 in the Czech Republic.
Pechandova K et al.
Genetic Testing and Molecular Biomarkers, 2012
Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients.
Seredina TA et al.
Bmc Medical Genetics, 2012
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug-drug interactions.
Gao Y et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2010
A bioinformatics approach for the phenotype prediction of nonsynonymous single nucleotide polymorphisms in human cytochromes P450.
Wang LL et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2009
Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards.
Peiró AM et al.
Pharmacological Research, 2009
Do single nucleotide polymorphisms in xenobiotic metabolizing genes determine breast cancer susceptibility and treatment outcomes?
Singh V et al.
Cancer Investigation, 2008
Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism.
Rodríguez-Antona C et al.
The Pharmacogenomics Journal, 2008
Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers.
López-Rodríguez R et al.
Pharmacological Research, 2008
Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa.
Parikh S et al.
Clinical Pharmacology and Therapeutics, 2007
Predicting drug response and toxicity based on gene polymorphisms.
Robert J et al.
Critical Reviews in Oncology/hematology, 2005
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
Niemi M et al.
Clinical Pharmacology and Therapeutics, 2005
A simple multiplex PCR method for the concurrent detection of three CYP2C8 variants.
Muthiah YD et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2004